C-Reactive Protein To Albumin Ratio As Prognostic Markers In Patients With Advanced Non-Small Cell Lung Cancers Treated With Tyrosine Kinase Inhibitors

Yi Lei,Jia Wu,Wang Guo,Yi He,Tingting Hu,Weimin Li

2018-01-01

Abstract:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have demonstrated a dramatic response rate and prolonged progression free survival (PFS) in patients harboring an activating EGFR mutation, but reliable prognostic markers are lacking. High C-reactive protein to albumin ratio (CAR) is a marker of host systemic inflammation and associated with poor outcome in various carcinomas, but has not been analyzed in advanced NSCLC patients treated with EGFR-TKI. We retrospectively analyzed 392 advanced NSCLC patients with activating EGFR mutations to examine the predictive value of CAR in the era of targeted therapy. The optimal cutoff level of CAR was set at 0.146 according to the receive operating characteristic (ROC) analysis. Survival analysis was determined using the Kaplan-Meier analysis and prognostic factors were determined using a Cox proportional hazards model. We found that high CAR (>= 0.146) was associated with poorer PFS and lower objective response rate. Subgroup analysis of both gefitinib and erlotinib showed that CAR was significantly associated with PFS. Multivariate analysis showed that pretreatment CAR was an independent predictive marker for PFS (HR: 1.48, 95% CI: 0.96-1.33). The findings of the present study demonstrated that advanced NSCLC patients with activating EGFR mutations who have pretreatment CAR values higher than 0.146 should be considered to have a high risk of early EGFR-TKI treatment failure.